Search Immortality Topics:

Page 6«..5678..2030..»


Category Archives: Nano Medicine

Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and…

Ponce Therapeutic's ("Ponce") lead product, ReBeaut, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDecell elimination gene therapy technology targeting senescent keratinocytes and fibroblasts in the skin

Speratum Biopharma ("Speratum") will receive an upfront payment, pre-clinical and clinical milestone payments, and a royalty on worldwide net sales of Licensed Products incorporating their technology

Ponce's exclusive license allows it to utilize the licensed technology to extend its gene therapy clinical portfolio to include any skin disorders, benign or malignant and all anti-aging applications, whether delivered locally or systemically

MIAMI, July 25, 2022 /PRNewswire/ -- Ponce Therapeutics, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, announced today that it had executed a worldwide, exclusive license to Speratum'sproprietary Nano-inand No-Pass Mimictechnologies to advance its lead product, ReBeaut, a state-of-the-art biotechnology platform to restore the youthful balance of aged or "senescent" and young, vital cells in the skin, targeting the senescent cells for elimination, providing a "reboot" of the skin's composition back to its youthful exuberance. Speratum's Nano-in is a proprietary, biocompatible polymer, LGA-PEI, that can condense with nucleic acids to form nanoparticles for drug delivery that can be used in vivo with a favorable pre-clinical toxicity profile. Nano-inwill be used to deliver Ponce's ApoptiCIDecell elimination technology into the skin via a proprietary dissolvable microneedle delivery platform. Ponce's exclusive license allows it to utilize the licensed technology to extend its gene therapy clinical portfolio to include any disorder of the skin, benign and malignant, including all dermatologic and cosmetic applications, skin-mediated gene therapy and skin-mediated delivery of small peptides, peptide-like molecules and other small molecules, and all anti-aging indications, whether delivered locally or systemically.

Story continues

Ponce Therapeutics, Inc.

PONCE Therapeutics, Inc. (https://poncetherapeutics.com), a biotech company leveraging the growing scientific knowledge surrounding the process of aging to develop products to arrest or reverse the aging process, was founded by Kevin Slawin, MD, Chairman and CEO and David Spencer, PhD., Chief Technology Officer, reuniting the team that founded Bellicum Pharmaceuticals and took it public in 2014 with a $55 million crossover Series C and a $161 million IPO. The team is retooling their original cell control technology with state-of-the-art advances ("ApoptiCIDe") towards their new goal of creating anti-aging products with a solid underlying scientific basis. Ponce Therapeutics began operations in January 2021 and operates in laboratory space in K2 Biolabs (https://k2-biolabs.com) in Houston, TX. Dr. Slawin is a founding Board Member of K2 Bio and both Drs. Slawin and Spencer are investors. Drs. Slawin and Spencer are also joined by Damian Young, Ph.D., CSO, and Kayvon Namvar, CFO, as the founders of DELIVER Therapeutics, Inc. (https://deliverthera.com)a company that plans to applynovel, high-throughput screening technologiescombinedwith chemical innovation to DELIVER therapeutics, including novel anti-aging therapeutics, that address the most difficult problems in clinical medicine and that is also situated at K2 Bio.

Ponce's founding lead investor, Rapha Capital, is an investment management firm focused on making strategic investments in early stage, non-public biotechnology companies, through special purpose, joint venture entities which it manages. Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon. In addition to founding Bellicum Pharmaceuticals, Inc.("Bellicum"), a publicly traded company listed on NASDAQ, he also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as Board Chairman of Imagin Medical, Inc. (https://imaginmedical.com), a publicly traded company (OTC: IMEXF), and FIZE Medical, Inc. (https://fizemedical.com), and a board member at 3DBio Therapeutics, Inc. (https://3dbiocorp.com/), and Demeetra AgBio, Inc. (http://demeetra.com). Together with Dr. Mitch Steiner, CEO of Veru, Inc., he is the Founder, CEO and Chairman of Miami MediCo.s (https://miamimedicos.com), a network of physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami.

"The science of aging has continued to mature and can now provide a scientific basis for technologies to reverse the aging process in humans. Proof of concept data in animal models demonstrates that removal of senescent cells from organs improves their function and imbues them with a more youthful profile," said Dr. Slawin. "I'm excited to be taking another important step towards the clinic in the anti-aging space, which I believe will quickly rival oncology in both value and interest" he added. "With this license, we are building the necessary technology platform to deliver our first product, beginning with the skin, allowing us to leverage an increasingly detailed, mechanistic understanding of aging to arrest or even reverse it," added Dr. Spencer.

"We are gratified to begin this collaboration with the team at Ponce that utilizes our novel technologies as part of their therapeutic platform," said Dr. Christian Marin-Mueller, the founder and CEO of Speratum and the inventor of Nano-inand No-Pass Mimic technologies. Dr. Thilo Bayrhoffer, Speratum Biopharma lead investor, treasurer, and member of the board added "Our patented technologies, combining synthetic biology with nanotechnology, are needed to develop modifiable and adaptable therapeutic platforms for targeted nucleic acid delivery. Following a research collaboration with Roche in 2021, this is the first commercial license for our technologies, and it reinforces our commitment to further Speratum' s therapeutic programs, including MiR198 targeting pancreatic cancer, which is expected to be in the clinic by 2024."

About Ponce Therapeutics, Inc.

Ponce Therapeutics "Anti-aging Technologies Based on Real Science and Developed by Real Scientists" Ponce Therapeutics is leveraging the growing scientific knowledge surrounding the process of aging to develop its first state-of-the-art biotechnology platform to restore the youthful balance of aged or "senescent" and young cells in the skin, targeting senescent cells for elimination. This provides a "reboot" of one's genetic program to turn the clock on one's skin back to its youthful exuberance. While initially focused on skin, Ponce is planning to develop a wide-ranging portfolio of anti-aging products based on the best science in the nascent anti-aging field. Ponce is headquartered in Miami, Florida with research facilities located in Houston, TX.

For more information about PONCE Therapeutics, email info@poncethera.comor visit https://poncetherapeutics.com

About Speratum Biopharma, Inc.

Speratum Biopharma, Inc. ("Speratum") is an innovative biotechnology company focused on research and development of targeted oligonucleotide delivery systems and nucleic acid therapeutics, including No-Pass MimicmicroRNA ("miRNA) for the treatment of cancer. The company was founded in 2014 with technologies licensed from Baylor College of Medicine ("Baylor"). Since then, Speratum has combined these with best-in class, proprietary nanotechnologies to generate a ground-breaking oligonucleotide and cell therapy platform. Speratum is currently in final pre-clinical stages of development for its first therapeutic, a small RNA tumor suppressor against pancreatic, ovarian, and other cancers that includes a proprietary RNA interference ("RNAi")-inducing mimic of miR-198, a naturally occurring microRNA involved in the pathogenesis of a number of solid cancers. Speratum's Nano-inand No-Pass Mimictechnologies are also being studied in other oligonucleotide research areas and therapeutic modalities such as circular RNA ("circRNAs").

For more information about Speratum Biopharma, please visit https://speratum.comor e-mail info@speratum.com

About Rapha Capital Management, LLC and Rapha Capital BioVentures Fund I, LP Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on strategic investments in early stage, non-public biotechnology companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I XIII. Rapha Capital Management offers alternative asset management services to the RCBV Fund, which has more recently been the vehicle for both new and follow-on investments managed by Rapha Capital Management.

For more information about Rapha Capital Management, email info@raphacapital.comor visit https://www.raphacap.com

(PRNewsfoto/Rapha Capital Management, LLC)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ponce-therapeutics-executes-worldwide-exclusive-license-to-speratum-biopharmas-nano-in-and-no-pass-mimic-nanoparticle-technologies-in-anti-aging-and-other-products-initially-for-skin-301591809.html

SOURCE Ponce Therapeutics, Inc.

Originally posted here:
Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and...

Posted in Nano Medicine | Comments Off on Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and…

What is medtech and where will it go next? – Verdict

Medtech startups are going from strength to strength. Investors have upped the funding dosage injected into the industry every year over the past decade.

However, that doesnt explain what medtech is or why venture capitalists are so eagerly betting on the sectors future.

But dont worry, weve got you covered.

Medtech stands for medicinal or medical technology. It is shorthand for technologies used within the medical realm.

Now, technically one could argue that things like scalpels, X-rays and stethoscopes would also fall under this category. After all, they were high-tech when they first popped into the scene and they are, undoubtedly, used by doctors around the planet.

However, the term medtech mainly applies to modern technologies with novel applications in healthcare. In other words: the term refers to high-tech solutions like artificial intelligence (AI) systems and robotics being used by doctors, nurses, pharmacologists and other medical practitioners.

And this prospect has clearly caught the imagination of investors

VCs have backed medtech en masse over the past decade. In 2013, investors injected $914m into the global industry across 220 deals, according to data from research firm GlobalData. The number of deals have climbed year on year since. In 2021, VCs bet $38.2bn on the industry across 1,161 deals.

However, there are signs that the flow of investment could be slowing down. As of July 25, only $11.7bn have been injected into the industry across 506 deals. This could be due to industry being caught up in the same macro economic whirlwinds the war in Ukraine, the end of the pandemic, rising inflation, new regulation to mention a few factors that now threatens to pop the tech bubble.

Time will tell whether investment will cool down like it seems to do for the tech industry in general.

Medtech has several applications. The first one worth mentioning is telemedicine. In a push to marry health with convenience, tech companies are developing ways that we can look after ourselves from home. Telemedicine became commonplace during the pandemic, and it has persevered; even now many continue to speak to their GPs over the phone. Following the pandemic, telemedicine services have been repurposed as one of the ways technology can help cities beat the next heatwave.

Beyond the pandemic, handheld and wearable remote patient monitoring devices transmit healthcare data to doctors and further innovations place the power to thrive directly into patients' pockets. For example, wearable blood-glucose monitors remind diabetic patients to take their insulin and specialist mobile games help children with ADHD sustain concentration for longer.

Medtech innovators are also increasingly tapping into the Internet of Things, (IoT), a system of wireless, interrelated and connected digital devices. By connecting medical devices to a server, doctors can, for instance, monitor patients' health remotely.

GlobalData estimates that the global market for IoT platforms for healthcare providers will jump from $10.6bn in 2020 to reach $13.3bn in 2025.

Medtech can also help patients in hospitals in a number of ways.

For instance, tricorders are handheld computers that use sensors, like cameras, to detect a range of health conditions. These time-saving devices, once merely a science-fiction, can now diagnose with at least the accuracy of a physician.

The list of new technologies that will permeate healthcare includes augmented reality (AR). AR headsets will allow surgeons to cycle through different scans of a patient during an operation. Other AR headsets will help to train medical students.

Robotics are already providing help during surgery. Doctors in Seattle already allow robotic appendages to lend a steady hand during minimally-invasive procedures on the brain.

AI has a plethora of applications in healthcare. To mention a few, AI can identify abnormalities on scans that might otherwise go overlooked. AI might also speed up clinical trials. Systems that simulate how a chemical will interact in the body are currently under development.

Interestingly, another AI has even formulated a potential medicine. Supercomputers during Covid-19 also helped to develop the vaccine that enabled us to get back to the new normal, whatever that is. Supercomputers are clusters of interconnected computers with an accumulated processing power that put todays fastest home desktops to shame.

AI have also been combined with robotics in order to improve the length and quality of life of patients suffering from motor neurone disease.

Fascinating developments in nanotechnology continue to broaden the horizons of medicine. Notably, nanomedicine can ensure that chemicals only reach targeted locations in the body. Radioactive medicines are encased in a nanostructure to protect organs, and when the medicine reaches the target location ultrasound is used to break open the casing.

The applications of technology in healthcare are vast and open ended. We have just scratched the surface of the wealth of possibilities in 21st Century medtech.

So it's unsurprising that another few CCs of VC funding for the medtech sector is just what the doctor ordered.

Excerpt from:
What is medtech and where will it go next? - Verdict

Posted in Nano Medicine | Comments Off on What is medtech and where will it go next? – Verdict

Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, Inc. a private biotechnology company located in Cambridge MA with a proprietary nano-technology HALOS platform (High-Affinity Ligands Of Siglecs), announced today the appointment of Tarek S. Hassan, MD, FASRS as Chief Development Officer and Senior Vice-President. He joins other leaders in the fields of retina and immunologic-based science and therapeutics, Drs. Mohamed Genead, David Callanan, Michael Tolentino, Derek Kunimoto, and Christopher Scott, as part of the executive management team.

Aviceda Therapeutics is an innovative clinical stage biotechnology company focused on developing transformative glyco-therapeutic drugs that modulate dysregulated inflammation in a diverse range of diseases that affect large unserved and underserved populations. Avicedas short-term focus is the initiation of the clinical trial for its lead product, AVD-104, a Ph II ready ophthalmic lead product for geographic atrophy (GA) secondary to dry AMD (dAMD). Dr. Hassan is ideally suited to manage the development of AVD-104 and move the company forward to bring its breakthrough therapies to the clinic, address significant unmet medical needs, and ultimately transform lives.

Aviceda is honored to have one of the most renowned and successful leaders in retina and strategic drug development join the Aviceda team in this key position. We believe that we have assembled the top team in ophthalmology and beyond. With our lead product about to enter clinical trials for GA associated with dry AMD, this is an ideal time for Tarek to join our management team. Given the broad potential of our HALOS technology pipeline, todays announcement marks a major step forward in advancing Aviceda as leading company in the field of retina and beyond, said Dr. Genead, co-founder and CEO of Aviceda Therapeutics.

I am honored to join the outstanding team of thought leaders in the fields of retina, glycobiology, and immune therapy at Aviceda, said Dr. Tarek Hassan. I am excited to complete the planning and oversee the execution of the Phase 2 trial for AVD-104 for GA associated with AMD. This critical indication affects a large patient population and has no current treatment. We have an outstanding opportunity to make major contributions towards finding a treatment for patients with this serious blinding disease, particularly through our innovative approach of developing immune modulators that act on the switches that turn pathologic mechanisms on and off. We see glyco-immune modulation as a powerful next generation mechanism for the treatment of many acute and chronic diseases of degeneration and inflammation, as well as diseases resulting from immune evasion.

About Tarek Hassan

Tarek S. Hassan, MD is Professor of Ophthalmology at Oakland University William Beaumont School of Medicine, Director of the Vitreoretinal Fellowship Training Program and Senior Partner at Associated Retinal Consultants in Royal Oak, Michigan. He is the current President of the Retina Hall of Fame, Immediate Past President of the Retina World Congress (RWC), Past President of the American Society of Retina Specialists (ASRS), and Past President of the Foundation of the ASRS. He has been on the Executive Board of Directors of the RWC for the past 6 years. He served on the Executive Committee of the ASRS and the Foundation of the ASRS for 12 years and on the Board of Directors of the ASRS for 22 years. He is a Founder and Director of the Retina Fellows Forum (22 years), Club Vit (24 years), and Retina Hall of Fame (6 years).

Dr. Hassan has an active academic clinical practice in which he is extensively involved in a wide variety of clinical vitreoretinal research studies. He has been principal investigator or co-investigator in more than 150 randomized clinical trials, authored and co-authored more than 230 papers in peer-reviewed journals, and written 9 books and/or book chapters for medical texts. He is Senior Associate Editor of the Journal of Vitreoretinal Diseases, as well as an editorial board member and scientific reviewer for other leading journals within ophthalmology and retina. He has given over 760 national and international presentations on many retinal topics and been awarded the American Academy of Ophthalmology (AAO) Achievement Award, the ASRS Senior Honor Award, and the AAO Senior Achievement Award. He was elected as an inaugural member of the Retina Hall of Fame in 2017. He founded, or co-founded several medical device and educational companies, and been granted numerous government-issued device patents.

Born in Houston, Texas, Dr. Hassan obtained his undergraduate, medical school, and residency training at the University of Michigan in Ann Arbor, Michigan and then completed a vitreoretinal diseases and surgery fellowship at Associated Retinal Consultants in Royal Oak.

About Aviceda Therapeutics Inc.

Aviceda is a private biotechnology company located in Cambridge MA with a proprietary nano-technology HALOS platform and an IND-ready ophthalmic lead product for (GA) secondary to dAMD.

Avicedas lead product, AVD-104, is an intravitreal nanoparticle using HALOS technology with a dual mechanism of action (MOA) for GA/dAMD on critical complement and inflammatory pathways.

Read the rest here:
Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development...

Posted in Nano Medicine | Comments Off on Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development…

Biologys hardest working pigments and MOFs – EurekAlert

image:Illustration of the wide range of electrocatalytic and photocatalytic processes and applications for porphyrin framework materials view more

Credit: Nano Research Energy, Tsinghua University Press

Some of the economic sectors that are the hardest to decarbonize would benefit from the emergence of substantially more efficient catalysts involved in energy conversion chemical reactions. A breakthrough here might depend upon the use of pigments widely deployed in biological processes integrated as a catalyst into novel and highly porous molecular structures that act sort of like sponges.

A paper describing the state of play in this field and the challenges it faces was published in the journal Nano Research Energyon May 29.

In recent years, porphyrins and metalloporphyrins have played an increasingly important role in biomimetic chemistry, solar energy utilization, medicine, and a great many other applications. But use of porphyrins in electrocatalysis and photocatalysis reactions central to many energy conversion processes useful for the clean transition was found to be unstable, deactivate, and difficult to recycle, which has limited the further development of these energy conversion technologies.

So scientists have begun to consider the integration of porphyrins as the organic ligands (the ion that binds to a central metal atom in a complex molecule) into synthetic molecular structures known as metal-organic frameworks (MOFs) and their twin, covalent-organic frameworks (COFs)known as porphyrin-based framework materials.

This should in principle deliver excellent electrocatalysis and photocatalysis performance as the MOF and COF structures are simple to synthesize and highly designed, thus much more controllable and structurally stable, said Yusuke Yamauchi, a co-author of the paper and researcher with the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland.

The researchers, who are themselves involved in porphyrin-based framework materials development, put together a review article describing the state of play in their field. Such review papers are necessary for young fields to advance as they clarify current understanding, discuss advances and challenges, identify research gaps and can even offer guidelines for policy and tips on best practice, Huan Pang, a co-author of the paper and the researcher with the School of Chemistry and Chemical Engineering at the Yangzhou University, China

The paper explores all the current and potential applications of porphyrin-based framework material catalysts, and finds that there remains great potential, but the field confronts several challenges.

In an economy of net-zero greenhouse gas emissions, not everything can be electrifiedparticularly long-haul heavy transportand so some form of clean fuels, such as carbon-neutral synthetic hydrocarbons, ammonia or hydrogen will be necessary. All these fuels involve the conversion of clean energywhether from the sun, wind, water or uraniuminto transportable and stable chemical energy. Part of this process requires the production of clean hydrogen through the use of electricity, light or heat to split water into its constituent elements, hydrogen and oxygen.

Hydrocarbons are composed of differing ratios of carbon and hydrogen, hence the name. Thus the clean, synthetic versions replacing their dirty fossil cousins will require drawing down carbon dioxide from the atmosphere and transforming it into various usable forms of carbon as an input to be married to the clean hydrogen. To draw down atmospheric carbon and make use of it is also known as carbon capture and utilization (CCU).

All these processes, and many others involved in the clean transition (the move from fossil fuels to clean technologies) such as the use of fuel cells and light collection, are in effect chemical reactions that convert energy from one form to another, more usable form. These chemical reactions require addition of substances known as catalysts that speed the reaction up. Some of those catalysts are extremely expensive such as platinum, or are not efficient enough for the end product to compete with fossil fuels, or produce their own environmental challenges.

Thus the hunt is on for more efficient, cheaper and cleaner catalysts such as porphyrin,

The development of efficient non-precious porphyrin-based framework material catalysts to replace precious metal catalysts remains a significant hurdle. The design and construction of porphyrin blocks currently mainly relies on a highly symmetrical design, which limits the diversity of porphyrin framework families and affects their potential catalytic applications. Novel structures that employ porphyrin units with asymmetric design should be considered to extend the substances utility.

The cost of preparing porphyrin framework materials remains high and so it is urgent that engineers develop new synthesis methods if these catalysts are to be taken up in large-scale industrial applications. Reducing the number of steps required in synthesis is an important research, but it is also extremely difficult to do this.

They conclude however that should such challenges be overcome, porphyrin-based framework materials could be a game-changer in the commercialisation of energy conversion processes essential for some of the sectors that are the very hardest to decarbonize.

Porphyrins are some of biologys hardest working substances. This class of pigments is deployed in a wide array of vital processes, from photosynthesis to breathing. Derivatives of these water-soluble, ring-shaped molecules that bind metal ions include chlorophylls in plants and the hemoglobins that carry oxygen in the blood of animals. They also enhance the catalytic activities of enzymes in a range of other life-giving chemical reactions. Metalloporphyrins are of particular interest with respect to the clean transition due to their role as catalysts in water splitting to produce hydrogen and oxygen.

##

About Nano Research Energy

Nano Research Energy is launched by Tsinghua University Press, aiming at being an international, open-access and interdisciplinary journal. We will publish research on cutting-edge advanced nanomaterials and nanotechnology for energy. It is dedicated to exploring various aspects of energy-related research that utilizes nanomaterials and nanotechnology, including but not limited to energy generation, conversion, storage, conservation, clean energy, etc. Nano Research Energy will publish four types of manuscripts, that is, Communications, Research Articles, Reviews, and Perspectives in an open-access form.

About SciOpen

SciOpen is a professional open access resource for discovery of scientific and technical content published by the Tsinghua University Press and its publishing partners, providing the scholarly publishing community with innovative technology and market-leading capabilities. SciOpen provides end-to-end services across manuscript submission, peer review, content hosting, analytics, and identity management and expert advice to ensure each journals development by offering a range of options across all functions as Journal Layout, Production Services, Editorial Services, Marketing and Promotions, Online Functionality, etc. By digitalizing the publishing process, SciOpen widens the reach, deepens the impact, and accelerates the exchange of ideas.

Nano Research Energy

Porphyrin-based framework materials for energy conversion

29-May-2022

Read the original post:
Biologys hardest working pigments and MOFs - EurekAlert

Posted in Nano Medicine | Comments Off on Biologys hardest working pigments and MOFs – EurekAlert

Nano Therapy Market 2022 Growth Is Expected To See Development Trends and Challenges to 2030 This Is Ardee – This Is Ardee

New York, United States Report Ocean published the latest research report on the Nano Therapy market. In order to comprehend a market holistically, a variety of factors must be evaluated, including demographics, business cycles, and microeconomic requirements that pertain precisely to the market under study. In addition, the Nano Therapy market study demonstrates a detailed examination of the business state, which represents creative ways for company growth, financial factors such as production value, key regions, and growth rate.

Key Companies Covered in theNano TherapyResearch areNanosphere Inc., Cristal Therapeutics, DIM, NanoMedia Solutions Inc., Luna, Nanobiotix, Sirnaomics Inc., Selecta Biosciences Inc., NanoBioMagnetics.n.nu, Nanospectra Biosciences Inc., Tarveda Therapeutics, Parvus Therapeutics, CytImmune Science Inc., Nanoprobes Inc., NanoBio Corporation, Smith and Nephewand other key market players.

TheNano Therapymarket revenue was $$ Million USD in 2016, grew to $$ Million USD in 2022, and will reach $$ Million USD in 2030, with a CAGR of % during 2022-2030.

The Centers for Medicare and Medicaid Services data estimates that the U.S. national healthcare expenditure surpassed US$ 4.1 trillion in 2020 and is forecast to reach US$ 6.2 trillion by 2028. According to the Commonwealth Fund, the U.S. expended nearly 17% of gross domestic product (GDP) on healthcare in 2018. Switzerland was the second-highest-ranking country, expending 12.2%. In addition, New Zealand and Australia devote only 9.3%.Request To Free Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=mai284010

According to the U.S. Bureau of Labor Statistics, employment in healthcare fields is forecast to grow 16% from 2020 to 2030, much quicker than the standard for all occupations, counting about 2.6 million new jobs. This estimated growth is mainly due to an elder population, showing to greater demand for healthcare services. The median annual wage for healthcare practitioners and technical fields (such as registered nurses,0020physicians and surgeons, and dental hygienists) was US$ 75,040 in May 2021, which was greater than the median annual wage for all occupations in the economy of US$ 45,760.

Market Overview

Nano therapy is a branch of nanomedicine that involves using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process known as targeting.

GlobalNano TherapyMarket Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries covers and analyzes the potential of the global Nano Therapy industry, providing statistical information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy Analysis, opportunities and forecasts. The biggest highlight of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19. At the same time, this report analyzed the market of leading 20 countries and introduce the market potential of these countries.

Most important types of Nano Therapy products covered in this report are:Nanomaterial and Biological DeviceNano Electronic BiosensorMolecular NanotechnologyImplantable Cardioverter-Defibrillators

Most widely used downstream fields of Nano Therapy market covered in this report are:Cardiovascular DiseaseCancer TherapyDiabetes TreatmentRheumatoid ArthritisOthers

Top countries data covered in this report:United StatesCanadaGermanyUKFranceItalySpainRussiaChinaJapanSouth KoreaAustraliaThailandBrazilArgentinaChileSouth AfricaEgyptUAESaudi Arabia

SPECIAL OFFER (Avail an Up-to 30% discount on this report) :-https://reportocean.com/industry-verticals/sample-request?report_id=mai284010

Chapter 1 is the basis of the entire report. In this chapter, we define the market concept and market scope of Nano Therapy, including product classification, application areas, and the entire report covered area.

Chapter 2 is the core idea of the whole report. In this chapter, we provide a detailed introduction to our research methods and data sources.

Chapter 3 focuses on analyzing the current competitive situation in the Nano Therapy market and provides basic information, market data, product introductions, etc. of leading companies in the industry. At the same time, Chapter 3 includes the highlighted analysisStrategies for Company to Deal with the Impact of COVID-19.

Chapter 4 provides breakdown data of different types of products, as well as market forecasts.

Different application fields have different usage and development prospects of products. Therefore, Chapter 5 provides subdivision data of different application fields and market forecasts.

Chapter 6 includes detailed data of major regions of the world, including detailed data of major regions of the world. North America, Asia Pacific, Europe, South America, Middle East and Africa.

Chapters 7-26 focus on the regional market. We have selected the most representative 20 countries from 197 countries in the world and conducted a detailed analysis and overview of the market development of these countries.

Chapter 27 focuses on market qualitative analysis, providing market driving factor analysis, market development constraints, PEST analysis, industry trends under COVID-19, market entry strategy analysis, etc.

Access full Report Description, TOC, Table of Figure, Chart, etc. @:-https://reportocean.com/industry-verticals/sample-request?report_id=mai284010

Key Points:Define, describe and forecast Nano Therapy product market by type, application, end user and region.Provide enterprise external environment analysis and PEST analysis.Provide strategies for company to deal with the impact of COVID-19.Provide market dynamic analysis, including market driving factors, market development constraints.Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis.Keep up with international market trends and provide analysis of the impact of the COVID-19 epidemic on major regions of the world.Analyze the market opportunities of stakeholders and provide market leaders with details of the competitive landscape.

Table of Content:

For More Information or Query or Customization Before Buying, Visit @:https://reportocean.com/industry-verticals/sample-request?report_id=mai284010

Key Benefits for Industry Participants & Stakeholders

Key Questions Answered in the Market Report

Request Full Report :-https://reportocean.com/industry-verticals/sample-request?report_id=mai284010

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATESTel:+1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com

Excerpt from:
Nano Therapy Market 2022 Growth Is Expected To See Development Trends and Challenges to 2030 This Is Ardee - This Is Ardee

Posted in Nano Medicine | Comments Off on Nano Therapy Market 2022 Growth Is Expected To See Development Trends and Challenges to 2030 This Is Ardee – This Is Ardee

Fast and ultrafast thermal contrast amplification of gold nanoparticle-based immunoassays | Scientific Reports – Nature.com

Setting up TCA readers with CW vs. pulsed lasers

To achieve ultra-high signal amplification fold on the GNP labels, the TCA system can be improved by increasing the laser energy fluence. During laser irradiation, the heat generation of a GNP,(dot{{Q}_{GNS}}), can be estimated as

$$dot{{Q}_{GNP}}={C}_{abs}bullet {I}_{0},$$

(1)

where ({C}_{abs}) is GNPs absorption cross section (unit: ({mathrm{mm}}^{2})), and ({I}_{0}) is the energy fluence of laser irradiation (unit: (mathrm{W}cdot{mathrm{mm}}^{-2})). Increasing ({I}_{0}) creates a higher photothermal response from GNPs ((dot{{Q}_{GNS}})), which could help lower TCAs detection limit of GNPs in LFA. In most previous studies, a CW laser at 532nm was used in TCA and the regular irradiation power on LFAs was set as~25mW10,11,13,15. The measured diameter of the laser spot on LFA was about 0.1mm13, whose average input energy fluence, ({I}_{0}), was estimated as 3.2(mathrm{W}cdot{mathrm{mm}}^{-2}) (Table 1).

To maximize the photothermal response of GNPs, the traditional CW laser was upgraded to a pulsed laser with higher energy fluence. Here, a 1064nm Nd:YAG laser (iWeld 980 Series, 120J, LaserStar Technologies, FL, USA) was used to provide a high-energy singular millisecond pulse, as shown in Supplementary Fig. S1a. As calibrated, the highest laser pulse energy was 60.64J within 20ms16. For a 2mm spot, the energy fluence from the pulsed laser was up to 955.4(mathrm{W}cdot{mathrm{mm}}^{-2}), about 300-fold higher than that in previous studies10,11,13,15. To maximize (dot{{Q}_{GNP}}) under the same laser irradiation, the GNS was chosen over other GNPs, such as gold nanorods (about 90nm in length and 15nm in width) which also absorb strongly at 1064nm, because GNS has larger ({C}_{abs}) than other GNPs as characterized in a previous study17. Table 1 compares the (dot{{Q}_{GNP}}) of different GNP-laser settings. The GNS-pulsed laser (400V) setting has the highest heat generation which can be as high as 2080-fold of that for the 30nm gold nanosphere (GNSp)-CW laser (25mW) setting. Thus, it was chosen to test the limit of TCA. However, less than maximum pulsed laser intensity (22.3(mathrm{W}cdot{mathrm{mm}}^{-2})) was used to test GNS-loaded NC membrane (model LFA) since it was prone to burn under more intensive irradiation.

To test the limit of TCA, both TCA readers equipped with CW laser and pulsed laser were set up to compare their limits of detection (LoDs) for GNPs precoated in NC membrane and on coverslips as immunoassay models. Their schematic setup is shown in Fig.1a,c. More details on CW laser TCA can be referred to our previous work9,13. Details of ultrafast TCA setup and characterization are provided in Supplementary Sect. S1. As compared between Fig.1b,d, different lasers enable different heating intensity and speed. When heating a GNP spot with an ms pulsed laser, the heating energy from pulsed laser was confined within the laser spot which, in turn, enabled a much higher temperature increase than CW laser heating (detailed in Supplementary Sect. S4). The temperature increase of a GNP spot can be done within ms by pulsed laser heating while CW laser would need many seconds to heat the spot. As summarized in Fig.1e, faster reading can be achieved with the pulsed laser ultrafast TCA (seconds) than CW laser TCA either with discrete or continuous reading algorithms (115min) as detailed in previous work9,13,14. Additionally, different temperature measurement products (IR camera vs. sensor) were used to fit with the lasers as summarized in Fig.1e.

TCA readers equipped with continuous-wave (CW) laser vs. pulsed laser. (a) Arrangement of the laser path, IR camera, and testing platform, such as a substrate coated with gold nanoparticle (GNP) spot, in the CW laser TCA reader. (b) Schematic record of temperature response of a GNP spot heated by CW laser. (c) Arrangement of the laser path, IR sensor, and testing platform in the ultrafast TCA reader equipped with an ms pulsed laser. The gray area was the field of view of the IR sensor, which depends on the alignment parameters, d and (theta) (detailed in Supplementary Sect. S1). (d) Schematic record of temperature response of a GNP spot read by pulsed laser. (e) Comparison of reading time, laser heating time scale, and temperature measurement products in ultrafast TCA vs. CW laser TCA with continuous and discrete reading algorithms.

In addition to lasers, GNP-loaded substrates being irradiated also impact the thermal responses. In general, substrates with lower thermal mass and higher tolerance for laser intensity against thermal damages will achieve higher thermal signals. Table 2 lists three substrates (NC membrane, plastics, and coverslip) that can be potentially used for immunoassays and testing the limit of TCA. NC membrane (widely used in LFAs) and coverslip were chosen as substrates to be tested in this study since they had significant differences in both thermal mass normalized by volume and maximum temperature without thermal damage.

To test the limit of TCA, we compared thermal signals of the (pulsed laser) ultrafast TCA with CW laser TCA when reading the same model LFAs (GNS-loaded NC membrane) as seen in Fig.2. The UVvis-NIR extinction spectrum of the GNS is shown in Supplementary Fig. S3. The intensity output of the pulsed laser was set at 22.3(mathrm{W}cdot{mathrm{mm}}^{-2}) (Table 1) to avoid thermal damage to NC membrane, whose thermal signals are shown in Fig.2a. For CW laser TCA, both traditional discrete reading and continuous reading (i.e., fast reading) were applied and results were plotted in Fig.2b,c, respectively. The CW laser intensity was set at 12.7(mathrm{W}cdot{mathrm{mm}}^{-2}) (100mW, Table 1), nearly twofold lower than that from ultrafast TCA. Compared with visual reading of model LFAs, TCA readings showed a 10- to 20-fold reduction in LoD for GNSs loaded in NC membrane, as shown in Fig.2ac. The ultrafast TCA had higher thermal signals than CW laser TCA for the controlled GNS concentrations, as compared in Fig.2d. However, it also had much higher background noise for the blank NC membrane (i.e., without GNSs). We speculate that this is due to the limitation of the IR sensor. Ideally, the acquisition time of the IR sensor should be at least tenfold smaller than the pulse width (3ms) to ensure the accuracy and consistency of the signal acquisition. Unfortunately, in our case, the IR sensor, which was chosen based on its small size to fit into laser chamber and price consideration, had a comparable acquisition time of 3ms (Fig.1e) despite the claim that it could show interpolated temperature at 1ms interval; this may contribute to some noise or inconsistency in the reading. In contrast, the CW laser TCA had a much faster temperature acquisition (16.7ms) than the laser heating time scale (seconds), thus with high reading consistency. Perhaps, as a result, the current ultrafast TCA setup did not show an apparent benefit in signal amplification to read model LFA compared to the fast TCA. The lowest LoD was achieved by the fast TCA reading (i.e., using CW laser and continuous reading algorithm), and was twofold lower than those from ultrafast TCA and the other discrete reading algorithm. Future optimization may consider a more advanced IR sensor, although a higher cost is expected. Alternatively, increasing lasers pulse width can reduce the impact of IR sensors inadequate sampling, which can also enhance thermal signals with a significant increase in laser energy fluence. Since NC membrane was prone to pyrolysis and burn under intensive laser heating (Table 2), another assay substrate (i.e., glass) was considered to test the limit of TCA in the next section.

Reading gold nanoparticles in nitrocellulose (NC) membrane as model lateral flow immunoassays (LFAs) by TCAs with continuous wave (CW) laser vs. pulsed laser. NC membrane was precoated with diluted silica-cored gold nanoshells (GNSs) as model test regions in lateral flow immunoassays. (a) Thermal signals from ultrafast TCA reading with a pulsed laser (22.3(mathrm{W}cdot{mathrm{mm}}^{-2}), 170V, 1.41J, 3ms) (red). (b) Thermal signals from CW laser TCA reading with a discrete reading algorithm (yellow). (c) Thermal signals from fast TCA reading with CW laser and continuous reading algorithm (blue). (d) Comparison of these thermal signals from different TCA readings. Round shadows: limits of detection (LoDs) for GNSs. Square shadow (gray): visual cutoff to read GNS spot in NC membrane (model LFA). Statistical significance is indicated with asterisks: ns: p>0.05; *p<0.05; **p<0.01. The GNS concentration in NC membrane was the projected surface concentration=volumetric concentration (times) membrane thickness.

For even higher signal amplification, proof-of-concept measurement was conducted by TCA reading of GNSs pre-coated on a glass coverslip as a model MIA, which can tolerate much higher irradiation intensity than either paper or plastic (see Table 2 and Fig.3a). To maximize the thermal signals in measurement, the maximal energy output of the pulsed laser (400V, 60.64J, 20ms pulse width, and 2mm spot size, ({I}_{0}=) 955.4(mathrm{W}cdot{mathrm{mm}}^{-2})) in ultrafast TCA was applied to detect GNSs on the coverslips in Fig.3b. A stricter metric (IUPAC, see Methods) was applied to extrapolate the LoD for GNSs on coverslip by ultrafast TCA reading rather than ANOVA analysis which was used as default for other measurements. To understand the benefit of coverslip, its thermal signals were compared with those of model LFAs with NC membrane read by ultrafast TCA but at lower pulse energy (1.41J) to avoid thermal damage (Fig.3c). Unlike model LFAs, the GNS-coverslips in Fig.3b were all subvisual due to poor visual contrast, while the visual cutoff of model LFAs was shown in Fig.3c. Regarding ultrafast TCA reading as compared in Fig.3d, the coverslips had higher thermal responses than model LFAs for the same GNS concentrations. The thermal LoD for GNSs on coverslip was also lower (~57-fold) than the visual LoD for model LFAs. This suggests that increasing laser pulse energy enabled higher thermal responses, which compensated for the large thermal mass of coverslip. Since coverslip has better thermal tolerance, 20ms pulse was applied, which was~6.7-fold longer than the acquisition time of IR sensor (3ms). Thus, the sensor sampling issue that may have influenced readings in the model LFA case (Fig.3c) was likely not an issue here (Fig.3b). Further modeling and discussion on substrate comparison for TCA are provided in Supplementary Sect. S4 to potentially achieve even higher thermal signals and thus better signal amplification from TCA reading. Certainly, finding a sensor that can operate under even shorter pulses with improved signal-to-noise will also help.

Testing the limit of thermal contrast amplification (TCA) by improving substrates for ultrafast TCA reading. Thermal signals were measured through ultrafast TCA reading silica-cored gold nanoshells (GNSs) precoated in nitrocellulose (NC) membrane and on coverslips at the same projected surface concentrations as model test regions in immunoassays. (a) Experimental tolerance of laser pulse energy by the tested GNS-NC membrane and GNS-coverslip systems. (b) Thermal signals from GNS-coverslips with maximal laser pulse energy (60.64J) over 20ms. (c) Thermal signals from GNS-NC membrane with laser pulse energy at 1.41J over 3ms to avoid thermal damage. (d) Comparison of these thermal signals from different substrates. Blue round shadow: limits of detection (LoDs) for GNSs in NC membrane. Square shadow (gray): visual cutoff to read GNS spot in NC membrane. Dashed line: extrapolated LoD for GNSs on coverslip by IUPAC metric. All the coverslip cases were subvisual. Statistical significance is indicated with asterisks: ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The GNS concentration in NC membrane was the projected surface concentration=volumetric concentration (times) membrane thickness.

Figure4a compared thermal signals from GNS-coverslip and GNS-NC membrane (or model LFA) when being read by their respective optimal TCAs. The LoD for GNSs in the coverslip case (1.24E3 GNSs/mm2) was still about 2.85-fold lower than that of the NC membrane case. This further proved that increasing the laser fluence can improve thermal response and signal amplification fold via TCA reading, and thus the sensitivity of immunoassays. Figure4a also showed that the background noise of blank samples for ultrafast reading of GNS-coverslip was around 1C, much higher than GNS-NC membrane with fast TCA reading, which may set the major limit to an even lower LoD. This noise might be due to the system error of the ultrafast TCA, absorption of laser energy by glass, etc. For even greater MIA sensitivity enhancement by TCA, future efforts would be needed to reduce the background noise.

(a) Comparison of thermal signals from diluted silica-cored gold nanoshells (GNSs) precoated in nitrocellulose (NC) membrane (model LAF) and on coverslips as model test regions in immunoassays when being read by their respective optimal thermal contrast amplification (TCA) systems. Model LFA was read by fast TCA (i.e., continuous-wave (CW) laser with a continuous reading algorithm) while coverslips were read by ultrafast TCA at maximal energy output. Blue round shadow: limits of detection (LoDs) for GNSs in NC membrane. Square shadow (gray): visual cutoff to read GNS spots in NC membrane. All the coverslip cases were subvisual. Dashed line: extrapolated LoD for GNSs on coverslip by IUPAC metric. (b) Summary of the LoDs for GNSs precoated in/on different substrates (i.e., NC membrane or coverslip) and read by different TCA systems. Their corresponding amplification folds were calculated by comparing them with visual cutoff for reading GNSs in NC membrane. For NC membrane, GNS concentration was the projected surface concentration=volumetric concentration (times) membrane thickness.

To summarize, Fig.4b shows the LoDs for GNSs measured on various substrates (NC membrane vs. coverslip) when being read by different TCA systems (CW laser vs. pulsed laser). The signal amplification folds were normalized by the visual cutoff of reading model LFAs, which is a conventional readout format for commercial LFAs. The coverslip and ultrafast TCA with maximal pulsed laser energy output had the maximal signal amplification (57-fold), followed by the model LFA with fast TCA reading (20-fold). When reading model LFAs, the discrete reading by CW laser TCA showed a similar amplification fold (tenfold) to the ultrafast TCA. It is also expected that the amplification fold by ultrafast TCA could be further improved by reducing the background noise and/or using a better IR sensor (faster response), despite the higher cost and other changes in TCA setup. For future ultrafast TCA-MIA applications, the consideration of assay kinetics and design was also discussed in Supplementary Sect. S5 apart from signal amplification. Overall, TCA is able to enhance signals for both LFAs and MIAs. MIA with TCA is promising for future ultrasensitive POC diagnostics, although further improvement in reducing background noise will be needed if further signal amplification is needed or required.

Here is the original post:
Fast and ultrafast thermal contrast amplification of gold nanoparticle-based immunoassays | Scientific Reports - Nature.com

Posted in Nano Medicine | Comments Off on Fast and ultrafast thermal contrast amplification of gold nanoparticle-based immunoassays | Scientific Reports – Nature.com